Vaccines
As many children go back to school, new waves of COVID-19 cases continue to surge. More data keeps coming in on potential vaccine risks and how they measure up against the risk of the disease. Here’s a look.
Merck has announced its vaxneuvance for pneumococcal disease in infants and has met key safety, tolerability, and immunogenicity endpoints in the first 30 days.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
mRNA has built its reputation as a type of vaccine to fight COVID-19, but its capabilities extend beyond vaccines into therapeutics and even diagnostics.
Moderna is expected to launch a human clinical trial as early as this week for an mRNA-based vaccine against HIV and indicated that it is looking for 56 people ages 18 to 50 who are HIV-negative.
This approval makes TICOVAC the only FDA-backed vaccine in the U.S. to protect people of all ages against the virus when visiting or living in TBE endemic regions.
By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone.
PRESS RELEASES